Related Experiment Video

Updated: Jun 18, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies

Nikhil G Thaker1, Ian F Pollack

  • 1Doris Duke Clinical Research Fellow, Departments of Neurosurgery, Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. thakerng@umdnj.edu

Expert Review of Neurotherapeutics
|December 3, 2009
PubMed

Insights

Malignant glioma (MG) treatments need improvement. Molecularly targeted therapies, especially combinations, show promise for overcoming tumor diversity and improving patient survival.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer therapeutics

Background:

  • Malignant glioma (MG) has a poor prognosis, with median survival around 1 year.
  • Current treatments (surgery, radiation, chemotherapy) offer limited efficacy.
  • Targeting molecular aberrations is key to developing more effective therapies.

Purpose of the Study:

  • To review single-agent and combination molecularly targeted therapies for MG.
  • To highlight strategies for overcoming MG's molecular diversity and heterogeneity.
  • To provide a rationale for combination therapies in treating malignant glioma.

Main Methods:

  • Literature review of molecularly targeted therapies for MG.
  • Analysis of signaling pathways implicated in glioma (e.g., growth-factor, PI3K/Akt/PTEN/mTOR, Ras/Raf/MEK/MAPK).
  • Summary of implemented single-agent and combination therapeutic strategies.

Main Results:

  • Molecularly targeted therapies offer novel treatment approaches.
  • Targeting specific pathways (growth-factor, PI3K/Akt/PTEN/mTOR, Ras/Raf/MEK/MAPK) is a focus.
  • Combination therapies are necessary due to MG's molecular complexity.

Conclusions:

  • Single agents may only be effective in a subset of MG patients.
  • Combination molecularly targeted therapies are crucial for improved outcomes.
  • Future treatments must address the heterogeneity of malignant glioma.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...